Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of $0.52, $0.01 better than the analyst estimate of $0.51. Revenue for the quarter came in at $50.1 million versus the consensus estimate of $52.52 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.